[A12-07] Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Last updated 02.05.2012

Project no.:
A12-07

Commission:
Commission awarded on 31.01.2012 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer, Skin and hair

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

02.05.2012

Considerable added benefit of ipilimumab in advanced melanoma

Advantages in overall survival, but disadvantages in the form of side effects

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2012-08-02 A G-BA decision was published.

G-BA documents on this decision (German only)

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.